ClinicalTrials.gg
RecruitingNCT05615818SAFIR-ABC10Updated May 19, 2026

Personalized Medicine for Advanced Biliary Cancer Patients

A Phase 3 interventional study of Futibatinib and Ivosidenib in Biliary Tract Neoplasms, sponsored by UNICANCER. Recruiting at 69 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by UNICANCER · Phase 3, Interventional, and Treatment

How we know · 21 judgments

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies in Biliary Tract Neoplasms with a site in France — 14 open to participants now, 21 under way, 8 of them phase 3. Biliary Tract Neoplasms · France.

Planned enrollment
3rd of 39
800 · median 215
Started
2024
with 5 others
Phase 3
9 of 45
4 open now
Primary completion
2027-06
later than 7 of 20 live
Registered
30th of 45
by date
Lead sponsor
3 of 45
UNICANCER

Among the 45 studies in Biliary Tract Neoplasms with a site in France, this one is the 3rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2024, is one of 9 in phase 3, reaches primary completion later than 7 of the 20 other live ones, and was the 30th registered.

Biliary Tract Neoplasms

521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.

Browse Biliary Tract Neoplasms studies →

Open to participants now

14 of the 45 studies in Biliary Tract Neoplasms with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 142 Biliary Tract Neoplasms studies recruiting now, 82 (58%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies in Biliary Tract Neoplasms with a site in France, or all of them as a file.
02

Study summary

The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.

The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, during which a molecular profile of the patient's tumour will be obtained, and (ii) a randomised comparative trial in which patients with disease control after 4 cycles of standard treatment, and whose tumour harbours a targetable molecular alteration, will be randomised (2:1) to receive either a matched targeted therapy or to continue with the standard treatment.

Read the detailed description

This is a Phase 3, multicentre, randomised, open-label trial to evaluate whether the introduction of molecular targeted therapy (MTT) as maintenance after 4 cycles of standard-of-care first-line systemic therapy (1L SoC) is superior to continuation of 1L-SoC in the treatment of patients with ABC. The trial is composed of two phases: (i) An initial screening phase to identify a suitable patient population, and (ii) a randomised comparative trial.

The aim of the screening phase is to identify a medically suitable population, to obtain a molecular profile of the patient's tumour, to collect baseline data concerning patient demographics and disease characteristics and to obtain pre-treatment blood and tumour samples for further translational research.

A genetic profile will be obtained from tumour-derived DNA and RNA samples by next-generation sequencing and from circulating tumour DNA. The trial Molecular Tumour Board will determine whether each patient harbours a targetable molecular alteration for one or more of the trial MTTs.

Patients with disease control after 4 cycles of 1L-SoC, who did not experience limiting toxicity, and whose tumour harbours at least one targetable molecular alteration, will be invited to participate in the randomised phase of the trial in which 159 eligible patients will be randomised (2:1) to receive either maintenance therapy with a matched MTT or to continue 1L-SoC treatment.

03

Conditions studied

  • Biliary Tract Neoplasms

Keywords

  • Biliary Tract Neoplasms
  • Targeted therapy
  • Personalised medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

SCREENING PHASE

Inclusion Criteria:

  1. Signed a written form prior to any trial specific procedures (Consent #1)
  2. -proven intrahepatic, perihilar or distal cholangiocarcinoma, or gallbladder carcinoma (ampullary carcinoma excluded)
  3. De novo or recurrent, locally advanced (non-resectable) or disease
  4. Availability of a suitable archived sample of primary or metastatic tumour tissue (frozen, or FFPE) or able to undergo a to obtain a suitable malignant tissue sample
  5. Aged ≥18 years
  6. (ECOG) performance status of 0 or 1
  7. Estimated >3 months
  8. Candidate for 1L-SoC therapy, or has initiated first cycle of 1L-SoC therapy
  9. Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements).

Exclusion Criteria:

  1. to 1L-SoC
  2. Patients who are candidates for locoregional therapy
  3. Contraindication to tumour biopsy in the absence of suitable archived sample of tumour tissue
  4. Prior anticancer therapy in the palliative setting. Adjuvant capecitabine allowed if completed ≥ 183 days prior to study entry
  5. Received more than 1 cycle of treatment with 1L-SoC
  6. Prior treatment with any of the MTT under investigation in the SAFIR-ABC10 study
  7. Current (other than ABC), with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial
  8. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
  9. Women who are pregnant or breast-feeding
  10. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
  11. Individuals deprived of liberty or placed under protective custody or guardianship

RANDOMISED TRIAL

Inclusion Criteria:

  1. Signed a written informed consent form prior to any trial specific procedures (Consent #2)
  2. Molecular profile showing the tumour harbours at least one targetable molecular alteration with a MTT in the study portfolio (as determined by the trial MTB)
  3. Disease control (stable or responsive) after 4 cycles of 1L-SoC, compared to a pre-treatment disease evaluation, as assessed by the investigator
  4. ECOG performance status of 0 or 1
  5. Presence of at least one evaluable lesion according to v1.1, or complete response to 12 weeks 1L-SoC
  6. Adequate bone marrow function: (ANC) ≥1.5 × 10⁹/L, count ≥100 × 10⁹/L, and ≥9 g/dL
  7. Adequate liver function: total level ≤1.5 × the (ULN) range (total bilirubin ≤3.0 ULN when the patient has documented Gilbert syndrome), and (AST) and alanine aminotransferase (ALT) levels ≤2.5 × ULN (AST and ALT ≤5 ULN when documented tumour liver involvement)
  8. Adequate renal function: estimated ≥ 60 mL/min according to the Cockcroft-Gault formula
  9. Adequate cardiac function: ≥50% at baseline as determined by either echocardiogram or multigated acquisition scan (MUGA)
  10. Adequate biliary drainage, with no evidence of ongoing infection
  11. Men, and women of (WOCBP) must agree to use adequate for the duration of trial participation and as required after completing study treatment. Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period.
  12. Women of childbearing potential must have a negative serum pregnancy test performed within 3 days before the date of randomisation
  13. Willing and able to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests, and other study procedures
  14. Affiliated to a social security system or in possession of equivalent private health insurance (according to local country health provision arrangements)

Exclusion Criteria:

  1. Disease progression occurring at any time prior randomisation, or toxicity that led to the discontinuation of the 1L-SoC before 4 full cycles have been delivered
  2. Toxicities from 1L-SoC not resolved to Grade ≤ 1 (according to version 5.0 the National Cancer Institute - [NCI-CTCAE v5.0]) before randomisation, with the exception of alopecia
  3. Contraindication or known to the MTT for the molecular alteration found in the patient, or any component in their formulation Note: For patients with multiple target alterations, contraindication to one MTT will not warrant exclusion if MTT to an alternative target is feasible.
  4. Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers
  5. Major surgery within 4 weeks of randomisation
  6. Radiotherapy within 7 days of randomisation
  7. Untreated central nervous system (CNS) metastases, symptomatic , or radiation treatment for CNS metastases within 4 weeks of start of study treatment. Stable, treated brain metastases are allowed (defined as subjects who are off and anticonvulsants and are neurologically stable with no evidence of radiographic progression for at least 4 weeks at the time of screening).
  8. cardiovascular disease (recent acute myocardial infarction, treated congestive heart failure [2 or above on the functional classification scale], recent thromboembolic or cerebrovascular events [within 12 weeks, excepted if related to indwelling catheter], known prolonged syndrome).
  9. Cardiorespiratory pathologies where hyperhydration is contraindicated.
  10. Manifestation of tinnitus and/or hearing loss since initiation of cisplatin therapy.
  11. Known . If leptomeningeal disease has been reported radiographically on baseline magnetic responance imaging (MRI), but is not suspected clinically by the investigator, the subject must be free of neurological symptoms.
  12. Concurrent malignancy (other than ABC), with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 5 years or more and are deemed at negligible risk for recurrence, are eligible for the trial
  13. Concomitant treatment with phenytoin in prophylactic use where this cannot be substituted for another therapy
  14. Known active virus or virus infection or (HIV) or known acquired immunodeficiency syndrome
  15. Any condition which in the Investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol
  16. Women who are pregnant or breast-feeding
  17. Participation in another therapeutic trial within the 30 days prior to entering the study. Participation in an observational trial would be acceptable
  18. Patients unwilling or unable to comply with the medical follow-up required by the trial because of geographic, familial, social, or psychological reasons
  19. Individuals deprived of liberty or placed under protective custody or guardianship

ADDITIONAL EXCLUSION CRITERIA FOR SPECIFIC MTTs:

Patients assigned to receive oral therapies:

  1. Inability or unwillingness to swallow pills
  2. History of malabsorption syndrome or other condition that would interfere with enteral absorption. For example, active intestine inflammation (e.g., Crohn's disease or ulcerative colitis) requiring therapy

Futibatinib:

  1. History and/or current evidence of any of the following disorders:

    1. Non-tumour related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator
    2. Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator
    3. Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant in the opinion of the Investigator
  2. Concomitant treatment with strong /P-gp inhibitors or strong or moderate CYP3A/P gp inducers where these cannot be substituted for another therapy.

Ivosidenib:

  1. Patients with history of torsade de pointes
  2. Concomitant treatment with digoxin where this cannot be substituted for another therapy
  3. Patients with a heart-rate corrected QT interval (using Fridericia's formula) (QTcF) ≥ 450 msec or other factors that increased the risk of QT prolongation or arrhythmic events (e.g. heart failure, hypokalemia, family history of long QT interval syndrome)
  4. Concomitant treatment with strong CYP3A4 inducers or dabigatran where these cannot be substituted for another therapy
  5. Concomitant treatment with medicinal products known to prolong the QTc interval, or moderate or strong CYP3A4 inhibitors where these cannot be substituted for another therapy
  6. Familial history of sudden death or polymorphic ventricular arrhythmia.
  7. Hypokalemia, hypomagnesemia or hypocalcemia where this cannot be corrected by supplementation

Zanidatamab:

  1. Treatment with anthracyclines within 90 days before first dose of zanidatamab and/or total lifetime load exceeding 360 mg/m2 Adriamycin® or equivalent
  2. Use of corticosteroids administered at doses equivalent to > 15 mg per day of prednisone within 2 weeks of first zanidatamab dosing unless otherwise approved by the coordinating investigator. Topical, ocular, intra-articular, intranasal, and/or inhalational corticosteroids are permitted
  3. QTcF > 470 ms
  4. History of myocardial infarction or unstable angina within 6 months prior to enrollment, troponin levels consistent with myocardial infarction, or clinically significant cardiac disease, such as ventricular arrhythmia requiring therapy, uncontrolled hypertension, or any history of symptomatic congestive heart failure
  5. Acute or chronic uncontrolled pancreatitis or Class C liver disease
  6. Clinically significant infiltrative pulmonary disease not related to lung metastases
  7. A history of life-threatening hypersensitivity to monoclonal antibodies or recombinant proteins

Neratinib \& trastuzumab:

  1. Patients with severe hepatic impairment (Child-Pugh Class C)
  2. Co-administration with the following medical products that are strong inducers of the CYP3A4/P-gp isoform of cytochrome P450, such as carbamazepine, phenytoin (antiepileptics), St John's wort (Hypericum perforatum) or rifampicin (antimycobacterial)
  3. Patients who are experiencing dyspnoea at rest due to complications of advanced malignancy or co-morbidities
  4. Hypersensitivity to murine proteins
  5. Current active pneumonitis within 90 days of receiving trastuzumab or a known history of interstitial lung disease

Encorafenib \& binimetinib:

  1. Patients with a history or current evidence of retinal vein occlusion or risk factors for retinal vein occlusion (e.g., uncontrolled glaucoma or history of hyperviscosity or hypercoagulability syndrome)
  2. Patients with concurrent neuromuscular disorders associated with elevated creatine phosphokinase (>ULN)
  3. Patients with hypokalemia, hypomagnesemia, or hypocalcemia (i.e. Serum potassium, magnesium or calcium \< lower normal limit)
  4. Patients with a QTcF ≥ 450 msec for men, or ≥ 470 msec for women
  5. Current or expected use of a strong inhibitor of CYP3A4
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    Experimental

    Molecular targeted therapy matched to genetic alteration carried by the tumour

    Drug: Futibatinib · Drug: Ivosidenib · Drug: Zanidatamab · Drug: Trastuzumab · Drug: Neratinib · Drug: Encorafenib · Drug: Binimetinib · Drug: Niraparib

  • Active comparator
    Control

    Continued standard of care treatment for first-line biliary tract cancer

    Drug: Cisplatin · Drug: Gemcitabine

Interventions

  • Dose 20 mg once a day (QD)

  • Dose 500 mg QD

    Also known as: Tibsovo

  • Dose: Patients \< 70 kg: 1800 mg every 3 weeks (Q3W), Patients ≥ 70 kg: 2400 mg Q3W

  • Loading dose 8 mg/kg, then 6 mg/kg Q3W (Combination with neratinib)

    Also known as: Zercepac

  • Dose: 240 mg QD (combination with trastuzumab)

    Also known as: Nerlynx

  • Dose: 450 mg QD (Combination with binimetinib)

    Also known as: Braftovi

  • Dose: 45 mg twice a day (BID) (Combination with encorafenib)

    Also known as: Mektovi

  • Dose: 200 mg QD or 300 mg QD

    Also known as: Zejula

  • Dose: 25 mg/m2 IV on days 1 and 8 Q3W (CISGEM)

  • Dose: 1000 mg/m2 IV on days 1 and 8 Q3W (CISGEM)

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    Time from randomisation to the first documented progression of disease (PD) as assessed by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first.

    Time frame: From randomisation to disease progression or death, up to 5 years.

Secondary outcomes

  1. Overall Survival (OS)

    The overall survival is the length of time from randomization that patients enrolled in the study are still alive.

    Time frame: From randomisation to death, up to 5 years.

  2. Objective response rate

    Objective response rate is defined as the proportion of patients achieving complete response (CR) or partial response (PR) (according to RECIST v1.1). Objective response rate will be presented as the best response achieved compared to the disease assessment performed at randomisation.

    Time frame: From randomisation, up to 5 years.

  3. Time to treatment failure

    Time from patient starting their allocated treatment to the date at which a patient first experiences a treatment failure event. The following will be considered as treatment failure events: early treatment discontinuation (regardless of reason), disease progression, death, starting a new treatment after completing scheduled treatment, withdrawal from the study due to any reason or loss to follow-up.

    Time frame: From randomisation to treatment failure event, up to 5 years.

  4. Progression-free survival after next line of treatment (PFS2)

    Time from randomisation to the date of second disease progression or death, whichever occurs first.

    Time frame: From randomisation to second disease progression or death, up to 5 years.

  5. Duration of response

    Duration of response is defined as the time from first documented response (compared to baseline measurement taken at randomisation) until the date of disease progression, as assessed by the investigator according to RECIST v1.1, or death from any cause whichever occurs first.

    Time frame: From response to disease progression or death, up to 5 years.

  6. Disease control rate

    Disease control rate is defined as the proportion of randomised patients achieving CR, PR, stable disease (SD)/no evidence of disease (NED) as assessed by the investigator according to RECIST v1.1.

    Time frame: From randomisation, up to 5 years.

  7. Percentage change in tumour size

    Taking the measurements at randomisation as the reference.

    Time frame: From randomisation, up to 5 years.

Other outcomes

  1. Feasibility of molecular screening

    The proportion of patients with an available MTB proposition at the time of the 3-month standard of care treatment evaluation.

    Time frame: Up to 3 months from start of treatment

  2. Quality of life questionnaire - Core 30 (QLQ-C30)

    Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials. The questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease. All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.

    Time frame: From baseline, every 3 cycles (every 9 weeks) until end of treatment, an average of 1 year

  3. Quality of life Questionnaire - Biliary tract cancer module (QLQ-BIL21)

    This EORTC cholangiocarcinoma and gallbladder cancer specific questionnaire is intended to supplement the QLQ-C30. The QLQ-BIL21 contains 21 items to assess symptoms. All items are rated on a four-point Likert-type scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), and are linearly transformed to a 0-100 scale.

    Time frame: From baseline, every 3 cycles (every 9 weeks) until end of treatment, an average of 1 year

  4. EuroQOL EQ-5D-5L questionnaire

    Developed by the EuroQol group, the self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials consists of a descriptive system and a visual analogue scale (VAS). The EQ-5D-5L descriptive system comprises five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each dimension has 5 levels (1 = "no problems", 2 = "slight problems", 3 = "moderate problems", 4 = "severe problems", and 5 = "extreme problems"). This questionnaire provide a 5-digit score which generate a health state profile. The VAS records the patient's self-rated health on a vertical visual analogue scale where the score range from 0 (The best health you can imagine) to 100 (The worst health you can imagine). The VAS is used as a quantitative measure of health outcome that reflects the patient's own judgement.

    Time frame: From baseline, every 3 cycles (every 9 weeks) until end of treatment, an average of 1 year

  5. Incidence of Adverse Events

    Safety and tolerability of the treatment will be evaluated using the National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5). NCI-CTCAE is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = "mild", 2 = "moderate", 3 = "severe", 4 = "life-threatening", and 5 = "death") determined by the investigator, will make it possible to assess the severity of the disorders.

    Time frame: From randomisation, up to 5 years

07

Study locations

41 of 69 sites recruiting
  • Cliniques universitaires de Bruxelles - Hôpital Erasme ULB
    Brussels, Belgium
    Not yet recruiting
    • Anne DEMOLS, MD · Contact
    • Anne DEMOLS, MD · Principal investigator
  • Cliniques universitaires Saint-Luc
    Brussels, Belgium
    Not yet recruiting
    • Ivan BORBATH, MD · Contact
    • Ivan BORBATH, MD · Principal investigator
  • Universitair Ziekenhuis Antwerpen (UZA)
    Edegem, Belgium
    Not yet recruiting
    • Timon VANDAMME, MD · Contact
    • Timon VANDAMME, MD · Principal investigator
  • Universitair Ziekenhuis Leuven
    Leuven, Belgium
    Not yet recruiting
    • Jeroen DEKERVEL, MD · Contact
    • Jeroen DEKERVEL, MD · Principal investigator
  • CHU Amiens Picardie
    Amiens, France
    Recruiting
    • Vincent HAUTEFEUILE, MD · Contact
    • Vincent HAUTEFEUILE, MD · Principal investigator
  • CHU d'Angers
    Angers, France
    Recruiting
    • Carole Vitellius · Contact
    • Carole Vitellius, MD · Principal investigator
  • Institut de cancerologie de l'Ouest - Angers
    Angers, France
    Recruiting
    • Victor SIMMET, MD · Contact
    • Victor SIMMET, MD · Principal investigator
  • Institut du Cancer Avignon Provence
    Avignon, France
    Recruiting
    • Clémence TOULLEC · Contact
    • Clémence TOULLEC, MD · Principal investigator
  • CHU de Besançon
    Besançon, France
    Recruiting
    • Christophe BORG · Contact
    • Christophe BORG, MD · Principal investigator
  • CHU de Bordeaux - Hôpital Haut-Leveque
    Bordeaux, France
    Not yet recruiting
    • Jean-Frédéric BLANC · Contact
    • Jean-Frédéric BLANC, MD · Principal investigator
  • Centre François Baclesse
    Caen, France
    Recruiting
    • Stéphane CORBINAIS · Contact
    • Stéphane CORBINAIS, MD · Principal investigator
  • Centre Jean Perrin
    Clermont-Ferrand, France
    Recruiting
    • Florence OSAER-POLYCARPE · Contact
    • Florence OSAER-POLYCARPE, MD · Principal investigator
  • CHU Estaing de Clermont Ferrand
    Clermont-Ferrand, France
    Recruiting
    • Marine JARY, MD · Contact
    • Marine JARY, MD · Principal investigator
  • APHP - Hopital Henri Mondor
    Créteil, France
    Recruiting
    • Christophe TOURNIGAND, MD · Contact
    • Christophe TOURNIGAND, MD · Principal investigator
  • CHU de Dijon
    Dijon, France
    Recruiting
    • Sylvain MANFREDI · Contact
    • Sylvain MANFREDI, MD · Principal investigator
  • CHU Grenoble Alpes
    Grenoble, France
    Not yet recruiting
    • Gael ROTH, MD · Contact
    • Gael ROTH, MD · Principal investigator
  • Groupe hospitalier mutaliste de Grenoble - Institut Daniel Hollard
    Grenoble, France
    Recruiting
    • Camille HERVE, MD · Contact
    • Camille HERVE, MD · Principal investigator
  • Centre Oscar Lambret
    Lille, France
    Recruiting
    • Aurélien CARNOT, MD · Contact
    • Aurélien CARNOT, MD · Principal investigator
  • CHU Lille
    Lille, France
    Recruiting
    • Anthony TURPIN, MD · Contact
    • Anthony TURPIN, MD · Principal investigator
  • CHU Dupuytren
    Limoges, France
    Recruiting
    • Frédéric THUILLIER, MD · Contact
    • Frédéric THUILLIER, MD · Principal investigator
  • Centre Leon Bérard
    Lyon, France
    Not yet recruiting
    • Philippe CASSIER, MD · Contact
    • Philippe CASSIER, MD · Principal investigator
  • Clinique Privée Jean Mermoz
    Lyon, France
    Not yet recruiting
    • Lea CLAVEL, MD · Contact
    • Lea CLAVEL, MD · Principal investigator
  • Hospices Civils de Lyon - Croix Rousse
    Lyon, France
    Recruiting
    • Marielle GUILLET, MD · Contact
    • Marielle GUILLET, MD · Principal investigator
  • APHM - CHU La Timone
    Marseille, France
    Not yet recruiting
    • Laétitia DAHAN, MD · Contact
    • Laétitia DAHAN, MD · Principal investigator
  • Hôpital Européen
    Marseille, France
    Recruiting
    • Nicolas BARRIERE, MD · Contact
    • Nicolas BARRIERE, MD · Principal investigator
  • Institut Paoli Calmettes
    Marseille, France
    Recruiting
    • Simon LAUNAY, MD · Contact
    • Simon LAUNAY, MD · Principal investigator
  • Institut de Cancer de Montpellier
    Montpellier, France
    Recruiting
    • Fabienne PORTALES, MD · Contact
    • Fabienne PORTALES, MD · Principal investigator
  • CHU Nantes - Hôtel Dieu
    Nantes, France
    Not yet recruiting
    • Yann TOUCHEFEU, MD · Contact
    • Yann TOUCHEFEU, MD · Principal investigator
  • Centre Antoine Lacassagne
    Nice, France
    Recruiting
    • Ludovic EVESQUE, MD · Contact
    • Ludovic EVESQUE, MD · Principal investigator
  • APHP - Hôpital Beaujon
    Paris, France
    Recruiting
    • Mohamed BOUATTOUR, MD · Contact
    • Mohamed BOUATTOUR, MD · Principal investigator
  • APHP - Hôpital Cochin
    Paris, France
    Recruiting
    • Romain CORIAT, MD · Contact
    • Romain CORIAT, MD · Principal investigator
  • APHP - Hôpital Saint Antoine
    Paris, France
    Recruiting
    • Helene BOUSSION DESLOGES, MD · Contact
    • Helene BOUSSION DESLOGES, MD · Principal investigator
  • Groupe Hospitalier Diaconesses Croix Saint-Simon
    Paris, France
    Not yet recruiting
    • Olivier DUBREUIL, MD · Contact
    • Olivier DUBREUIL, MD · Principal investigator
  • Institute Mutualiste Montsouris
    Paris, France
    Recruiting
    • David MALKA, MD · Contact
    • David MALKA, MD · Principal investigator
  • CH de Pau
    Pau, France
    Recruiting
    • Juliette THAURY, MD · Contact
    • Juliette THAURY, MD · Principal investigator
  • CHU Poitiers
    Poitiers, France
    Recruiting
    • David TOUGERON, MD · Contact
    • David TOUGERON, MD · Principal investigator
  • CH Cornouaille
    Quimper, France
    Recruiting
    • Christophe AGNELLO, MD · Contact
    • Christophe AGNELLO, MD · Principal investigator
  • CHU de Reims
    Reims, France
    Recruiting
    • Elia GIGANTE, MD · Contact
    • Elia GIGANTE, MD · Principal investigator
  • Institut Jean Godinot
    Reims, France
    Recruiting
    • Damien BOTSEN, MD · Contact
    • Damien BOTSEN, MD · Principal investigator
  • Centre Eugène Marquis
    Rennes, France
    Recruiting
    • Julien Edeline · Contact
    • Julien Edeline, MD · Principal investigator
  • CHU Charles Nicolle
    Rouen, France
    Not yet recruiting
    • Frederic DI FIORE, MD · Contact
    • Frederic DI FIORE, MD · Principal investigator
  • Institut Curie - Saint Cloud
    Saint-Cloud, France
    Not yet recruiting
    • Cindy NEUZILLET, MD · Contact
    • Cindy NEUZILLET, MD · Principal investigator
  • Institut de Cancerologie de l'Ouest
    Saint-Herblain, France
    Not yet recruiting
    • Amélie MALLET, MD · Contact
    • Amélie MALLET, MD · Principal investigator
  • Hôpital Foch
    Suresnes, France
    Recruiting
    • Jaafar BENNOUNA, MD · Contact
    • Jaafar BENNOUNA, MD · Principal investigator
  • CHU Toulouse
    Toulouse, France
    Recruiting
    • Nadim FARES, MD · Contact
    • Nadim FARES, MD · Principal investigator
  • CH Valence
    Valence, France
    Recruiting
    • Hélène FOISY, MD · Contact
    • Hélène FOISY, MD · Principal investigator
  • CHRU de Nancy
    Vandœuvre-lès-Nancy, France
    Recruiting
    • Marie MULLER, MD · Contact
    • Marie MULLER, MD · Principal investigator
  • APHP - Hôpital Paul Brousse
    Villejuif, France
    Not yet recruiting
    • Olivier ROSMORDUC, MD · Contact
    • Olivier ROSMORDUC, MD · Principal investigator
  • Gustave Roussy
    Villejuif, France
    Recruiting
    • Antoine Hollebecque · Contact
    • Antoine Hollebecque, MD · Principal investigator
  • Queen Elizabeth Hospital
    Birmingham, United Kingdom
    Recruiting
    • Yuk Ting MA, MD · Contact
    • Yuk Ting MA, MD · Principal investigator
  • Bristol Haematology and Oncology Centre
    Bristol, United Kingdom
    Recruiting
    • Stephen FALK, MD · Contact
    • Stephen FALK, MD · Principal investigator
  • Addenbrooke's Hospital
    Cambridge, United Kingdom
    Not yet recruiting
    • Pippa CORRIE, MD · Contact
    • Pippa CORRIE, MD · Principal investigator
  • Castle Hill Hospital
    Cottingham, United Kingdom
    Not yet recruiting
    • Anthony MARAVEYAS, MD · Contact
    • Anthony MARAVEYAS, MD · Principal investigator
  • St James's Hospital
    Leeds, United Kingdom
    Not yet recruiting
    • Alan ANTHONEY, MD · Contact
    • Alan ANTHONEY, MD · Principal investigator
  • Clatterbridge Cancer Centre NHS Foundation Trust
    Liverpool, United Kingdom
    Not yet recruiting
    • Daniel PALMER, MD · Contact
    • Daniel PALMER, MD · Principal investigator
  • Guy's & St Thomas' Hospital
    London, United Kingdom
    Not yet recruiting
    • Paul ROSS, MD · Contact
    • Paul ROSS, MD · Principal investigator
  • Hammersmith Hospital
    London, United Kingdom
    Recruiting
    • Harpreet WASAN, MD · Contact
    • Harpreet WASAN, MD · Principal investigator
  • Royal Free Hospital
    London, United Kingdom
    Not yet recruiting
    • Roopinder GILLMORE, MD · Contact
    • Roopinder GILLMORE, MD · Principal investigator
  • Royal Marsden Hospital
    London, United Kingdom
    Recruiting
    • Sheela RAO, MD · Contact
    • Sheela RAO, MD · Principal investigator
  • University College London
    London, United Kingdom
    Recruiting
    • John BRIDGEWATER, MD · Contact
    • John BRIDGEWATER, MD · Principal investigator
  • Maidstone Hospital
    Maidstone, United Kingdom
    Not yet recruiting
    • Justin WATERS, MD · Contact
    • Justin WATERS, MD · Principal investigator
  • The Christie Hospital
    Manchester, United Kingdom
    Not yet recruiting
    • Mairead MCNAMARA, MD · Contact
    • Mairead MCNAMARA, MD · Principal investigator
  • Mount Vernon Cancer Centre
    Northwood, United Kingdom
    Recruiting
    • Vasiliki MICHALAREA, MD · Contact
    • Vasiliki MICHALAREA, MD · Principal investigator
  • Nottingham University Hospital
    Nottingham, United Kingdom
    Recruiting
    • Aurora ARVIND, MD · Contact
    • Aurora ARVIND, MD · Principal investigator
  • Churchill Hospital
    Oxford, United Kingdom
    Not yet recruiting
    • Paul MILLER, MD · Contact
    • Paul MILLER, MD · Principal investigator
  • North West Anglia NHS Foundation Trust
    Peterborough, United Kingdom
    Not yet recruiting
    • Ankit RAO, MD · Contact
    • Ankit RAO, MD · Principal investigator
  • Weston Park Cancer Centre
    Sheffield, United Kingdom
    Not yet recruiting
    • Ahmad SABBAGH, MD · Contact
    • Ahmad SABBAGH, MD · Principal investigator
  • Southampton General Hospital
    Southampton, United Kingdom
    Not yet recruiting
    • Tim IVESON, MD · Contact
    • Tim IVESON, MD · Principal investigator
  • Singleton Hospital
    Swansea, United Kingdom
    Not yet recruiting
    • Steve KIHARA, MD · Contact
    • Steve KIHARA, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Unicancer will share de-identified individual data that underlie the results reported. A decision concerning the sharing of other study documents, including protocol and statistical analysis plan will be examined upon request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Unicancer will consider access to study data upon written detailed request sent to Unicancer, from 6 months until 5 years after publication of summary data.

Access criteria: The data shared will be limit to that required for independent mandated verification of the published results, the applicant will need authorization from Unicancer for personal access, and data will only be transferred after signing of a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2022
First posted
Nov 14, 2022
StartActual
Jul 18, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2028
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05615818
Lead sponsor
UNICANCER
Collaborators
Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Jul 18, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
May 19, 2026

Study contacts

Marta Jimenez
Contact
m-jimenez@unicancer.fr
+33 (0) 1 44 23 55 58
Malka David, MD
principal investigator · Institut Mutualiste Montsouris
Julien Edeline, MD
principal investigator · Centre Eugène Marquis
Ivan Borbath, MD
principal investigator · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
John Bridgewater, MD
principal investigator · University College London Cancer Institute
Juan W Valle
principal investigator · University of Manchester and The Christie NHS Foundation Trust

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Futibatinib · Ivosidenib · Zanidatamab · Trastuzumab · Neratinib · Encorafenib · Binimetinib · Niraparib

Start the discussion